State Street SPDR S&P Biotech ETF (XBI)
| Assets | $7.62B |
| Expense Ratio | 0.35% |
| PE Ratio | n/a |
| Shares Out | 65.13M |
| Dividend (ttm) | $0.04 |
| Dividend Yield | 0.04% |
| Ex-Dividend Date | Sep 22, 2025 |
| Payout Frequency | Quarterly |
| Payout Ratio | n/a |
| Volume | 10,304,951 |
| Open | 114.81 |
| Previous Close | 115.18 |
| Day's Range | 113.47 - 115.52 |
| 52-Week Low | 66.66 |
| 52-Week High | 116.18 |
| Beta | 0.88 |
| Holdings | 135 |
| Inception Date | Jan 31, 2006 |
About XBI
Fund Home PageThe State Street SPDR S&P Biotech ETF (XBI) is an exchange-traded fund that is based on the S&P Biotechnology Select Industry index. The fund tracks an equal-weighted index of US biotechnology stocks. XBI was launched on Jan 31, 2006 and is issued by State Street.
Top 10 Holdings
21.46% of assets| Name | Symbol | Weight |
|---|---|---|
| Revolution Medicines, Inc. | RVMD | 2.54% |
| Avidity Biosciences, Inc. | RNA | 2.46% |
| Insmed Incorporated | INSM | 2.23% |
| Regeneron Pharmaceuticals, Inc. | REGN | 2.11% |
| Madrigal Pharmaceuticals, Inc. | MDGL | 2.10% |
| Exact Sciences Corporation | EXAS | 2.05% |
| Natera, Inc. | NTRA | 2.03% |
| BridgeBio Pharma, Inc. | BBIO | 2.00% |
| Amgen Inc. | AMGN | 1.99% |
| Incyte Corporation | INCY | 1.94% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Sep 22, 2025 | $0.02665 | Sep 24, 2025 |
| Jun 23, 2025 | $0.0073 | Jun 25, 2025 |
| Mar 24, 2025 | $0.00525 | Mar 26, 2025 |
| Dec 23, 2024 | $0.00269 | Dec 26, 2024 |
| Sep 23, 2024 | $0.01523 | Sep 25, 2024 |
| Jun 24, 2024 | $0.11478 | Jun 26, 2024 |
Performance
XBI had a total return of 24.57% in the past year, including dividends. Since the fund's inception, the average annual return has been 10.58%.
News
3 Best Healthcare Stocks: Quant Strong Buys From Goldman's 'Alpha' List
The healthcare sector's renewed momentum offers fertile ground for investors wanting to outperform by picking the best stocks from the broader indexes. Goldman Sachs identified 29 healthcare stocks in...
XBI: Biotech Funding Condition Recovery Could Be Overdue
US Biotech is lagging other categories in terms of IPO and M&A, but could be overdue for a recovery with capital costs falling. Funding conditions are important for XBI which contains plenty of reflex...
XBI: An Equal Weight ETF On Biotech That Amplifies Its Speculative Component
State Street SPDR S&P Biotech ETF (XBI) has surged nearly 30% YTD, regaining the attention of Wall Street. The outperformance is due to an equal-weight structure, which makes it a high-beta instrument...
If M&A continues at this pace you want to be long Biotech into next year, says Mizuho's Jared Holz
Jared Holz, Mizuho, joins 'Fast Money' to talk the uptick in biotech and pharma M&A, what it is signaling, and how to play it.
Final Trades: Taiwan Semi, HealthEquity, CBOE Global Markets and the XBI
The Investment Committee give you their top stocks to watch for the second half.
Biotech is back and a constructive place to put money to work, says Piper Sandler's Craig Johnson
Craig Johnson, Piper Sandler chief market technician, joins 'The Exchange' to discuss the market technicals, if its a real market rotation and much more.
Investing In Health Stocks - How Policy Clarity Is Opening Doors
The healthcare sector has experienced one of its most significant de-ratings in 35 years, with valuations now at a 30% discount to the broader market. Healthcare trades at historical valuation discoun...
Top 6 ETFs To Watch As Wall Street's Strongest Six Months Begin
Right now ahead of Halloween, the real suspense might be in ETF investing strategies. With markets seesawing between hopes for rate cuts and the resilience of earnings, investors are dusting off one o...
3 Investable Laggards In An Overbought Market
The market continues to trade deeper in overbought territory based on most traditional valuation metrics. Most of the gains over the past three years have been driven by tech giants riding the AI Revo...
3 Biotech Stocks I Am Accumulating
The biotech sector has underperformed the market for many years now, but there are reasons to be optimistic about this area of the market. Many biotech/biopharma stocks also make good covered call tra...
Biotech Stocks Have Struggled Since 2021. Why They're Coming Back.
Too many questionable start-ups went public during the pandemic, when the sector was hot. Now, after over four years of pain, the weak have failed, rates are falling, and M&A looks to be on the upswin...
RTW Investments' Rod Wong: Expect more deals in biotech space
Rod Wong, RTW Investments CIO & Managing Director, joins CNBC's 'Money Movers' to discuss J&J's reported interest in buying Protagonist Therapeutics, whether he expects more consolidation in the secto...
Trade Tracker: Joe Terranova buys more XBI
Joe Terranova, senior managing director at Virtus Investment Partners, joins CNBC's "Halftime Report" to explain why he's buying XBI again. The committee share their health care strategy.
How to trade the health care break out
The health care sector up 6.5% in one week. The Investment Committee debate how to trade the space.
3 Reasons To Be Optimistic Around Biotech In Q4
The biotech sector has been on the move over the past month, outpacing the returns of the S&P 500 and the NASDAQ over that time. One key reason for this recent surge is that M&A activity is increasing...
Final Trades: SoFi Technologies, Clearway Energy, SPDR S&P Biotech ETF and CrowdStrike
The Investment Committee's top stock picks are in—here's what they're watching now.
Biotech Sector Shows No Signs of Slowing. 3 Stocks That Make the Grade.
Last week, the SPDR S&P Biotech ETF surged 6%.
Trump's Biotech Playbook Ignites $350 Billion Investment Blitz
Biotech is back – and it's playing for keeps. President Donald Trump's second-term policies have unleashed a staggering ~$350 billion surge in U.S.-based pharmaceutical and biotech investments, from d...
Real assets in biotech serving big markets the Street is finally noticing, says Mizuho's Jared Holz
Jared Holz, Mizuho healthcare strategist, joins 'Power Lunch' to discuss the change in sentiment in the healthcare sector, the differences in the biotech ETFs and much more.
Healthcare industry can handle and absorb tariffs, says Mizuho's Jared Holz
Jared Holz, Mizuho, joins 'Power Lunch' to discuss what tariffs mean for the pharma industry, what could be a blockbuster for Eli Lilly and much more.
XBI: Surprise Exit Of A Tough Regulator At The FDA
XBI has rebounded over 20% since lows in April, despite changes at the FDA that could have signaled a tougher regulatory environment. Vinay Prasad was only appointed in May, but is now leaving the FDA...
Evercore ISI's Umer Raffat on finding value in the beaten-down health care sector
Umer Raffat, Evercore ISI senior analyst, joins 'The Exchange' to discuss if there's a turnaround coming for the health care sector.
Trump threatens 50% tariffs on copper, 200% on pharmaceuticals
However, the President did not disclose when the tariffs would take effect.
It is time for a move higher in biotech, says Mizuho's Jared Holz
Jared Holz, Mizuho, joins 'Closing Bell Overtime' to discuss if the biotech sector is ready for a breakout.
Biotech Looks Ready To Run, But ETFs, Which One? IBB Vs. XBI
IBB and XBI are similar in many ways, but their relative past performance does not tell the story. IBB is more concentrated, and that is ultimately why I prefer it to XBI. Both ETFs target a similar o...
Pharma companies need to beef up M&A right now, says Mizuho's Jared Holz
Jared Holxz, Mizuho, joins 'Fast Money' to talk competition in the obesity drug space.
Home builders lose confidence, resort to price cuts as buyers steer clear of housing market
Builders' confidence in the housing market sank in June, the National Association of Home Builders said.
Trump is right about drug prices. He's just going about it all wrong.
The stock market doesn't believe the president about prescription drugs.
Trump Declares War On Pharma Drug Pricing, But The Stocks Aren't Tanking - Yet
President Trump has announced today he plans to reduce U.S. drug prices by 30-80% via an Executive Order, targeting Big Pharma's high costs and profits. U.S. drug prices are significantly higher (up t...
StemPoint's Michelle Ross breaks down navigating the pharmaceutical sector volatility
Michelle Ross, StemPoint Capital CIO, joins 'Closing Bell' to discuss health care's weak week and how to navigate pharma volatility.
New vaccine chief rocks pharmaceutical stocks
CNBC's Angelica Peebles joins 'Squawk on the Street' to discuss how the biotech and pharma industry is reacting to a new FDA chief of vaccines appointed by President Trump.
We're in a pharma stock pickers market, says Kessef's Len Yaffe
Len Yaffe, Kessef Capital Management, joins 'Fast Money' to talk opportunities in the pharma stock space.
Sell into strength in pharma, says Mizuho's Jared Holz
Jared Holz, Mizuho, joins 'Fast Money' to talk a rebound in biotech stocks and what new tariffs mean for the pharmaceuticals space.
How to Play the Biotech Meltdown in the Age of RFK Jr. and Tariffs
Political pressure and persistently high interest rates have some wondering if the industry's model is broken.
BMO's Siegerman talks the impact of tariffs on pharmaceutical stocks
Evan Seigerman, BMO, joins 'Fast Money' to talk the impact of tariffs on pharma space.
Vaccine stocks fall following FDA resignation
Dr. Kavita Patel joins 'Fast Money' to talk the impact of FDA and HHS changes on vaccines, public health policy, and more.
Drug stocks sink as FDA's top vaccine official is ousted in Trump overhaul
Shares of U.S. drugmakers fell on Monday after reports that the Food and Drug Administration's top vaccine official was forced to resign, the most high-profile exit at the regulator as the Trump admin...
Stifel's Paul Matteis says look for biotech names not dependent on the FDA amid sector uncertainty
Paul Matteis, Stifel head of biotech research, joins 'The Exchange' to discuss the biotech trade under a new FDA amid the top vaccine official resigning.
Single stock picking is the only way to make money in biotech, says Mizuho's Jared Holz
Jared Holz, Mizuho health care equity strategist, joins 'Power Lunch' to discuss investing in biotech and the oversaturation in the sector.
Trade Tracker: Joe Terranova sells the XBI, buys Amgen
Joe Terranova, Senior Managing Director for Virtus Investment Partners, joins CNBC's "Halftime Report" to detail his latest portfolio moves.
Invest In A New Biotech Bull Market With XBI And IBB
Biotech stocks are oversold. This near-term bottom might be the start of a long-term bull run. IBB and XBI offer different advantages. IBB can benefit from the flight to safety trade. XBI provides mor...
Seeking Stocks With Vitality In The Volatile Healthcare Sector
Investors cooled to the healthcare sector in 2024, which dramatically trailed global and US equity markets for the year. any investors are now asking: how will the policy changes under a new US admini...
Shareholder Group Led by Founder Mina Sooch Nominates Majority Slate of Director Candidates to the Board of Opus Genetics, Inc.
Current Board's Strategic, Management, and Capital Allocation Failures Have Driven an 80% Stock Decline Over Last 22 Months
XBI: Diverse Holding Amid Strong Catalysts, Buy
SPDR® S&P Biotech ETF is a strong investment due to rising demand for biotech solutions addressing chronic diseases and its diverse, equal-weighted portfolio. XBI's equal-weighting strategy reduces co...
3 Biotech Stocks With Notable Insider Buying
Small biotech stocks have struggled recently, with the SPDR® S&P Biotech ETF down over 15% in the past ten weeks. The pullback has presented significantly lower entry points on myriad small and mid-ca...
Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025
This article will provide an in-depth analysis of drugs being developed to combat cancer. Big Pharma is keenly interested in the global cancer therapeutics market, which is expected to exceed $400 bil...